What Quince’s failed NEAT trial reveals about rare pediatric trial design risks

Quince Therapeutics ends clinical development of eDSP for A-T after Phase 3 failure. Find out what this means for its platform and future strategy.

Quince Therapeutics ends clinical development of eDSP for A-T after Phase 3 failure. Find out what this means for its platform and future strategy.